Every Form 4 that Kura Oncology, Inc. (KURA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KURA filings page.
Kura Oncology, Inc. Chief Legal Officer Teresa Brophy Bair sold 8,442 common shares at $10.4973 per share on September 28, 2026, leaving her with 187,002 shares held directly. The sale was reported as a sell-to-cover for taxes associated with vesting 1/6th of the shares underlying performance-based restricted stock units granted May 31, 2023. The transaction was reported under a Rule 10b5-1 trading plan.
Kura Oncology, Inc. Chief Operating Officer Kathleen Ford reported direct sales of 6,906 common shares on September 28, 2026, at $10.4973 per share and 3,668 shares on September 29 at a weighted-average $10.7516 per share. The September 28 sale was a sell-to-cover for taxes associated with vesting 1/6th of the underlying shares of performance-based restricted stock units; the September 29 shares were acquired upon vesting of performance restricted stock units on September 27. The sales were effected under a Rule 10b5-1 trading plan adopted May 29, 2026.
Kura Oncology, Inc.'s Chief Medical Officer, Mollie Leoni, reported direct sales of 12,448 common shares at $10.4973 per share on September 28, 2026, and 28,802 shares at a weighted average $10.7481 per share on September 29, 2026. The September 28 sale covered taxes tied to vesting one-sixth of the underlying performance-based restricted stock units after a development milestone was determined to have been met on September 27, 2026. The September 29 sale was made under a Rule 10b5-1 trading plan adopted on March 19, 2026; trades ranged from $10.53 to $10.89.
Kura Oncology, Inc. SVP, Finance & Accounting Thomas James Doyle sold 4,607 shares of common stock on September 28, 2026, at $10.4972 per share in a tax sell-to-cover tied to vesting of 1/6th of the underlying performance-based restricted stock units. After the sale, he directly held 142,428 shares; a separate indirect holding lists 500 shares through his spouse’s 401(k). The direct post-transaction total includes 1,868 shares acquired on May 17, 2026, under the Employee Stock Purchase Plan. No Rule 10b5-1 plan is reported.
Kura Oncology, Inc. Chief Commercial Officer Brian T. Powl reported selling 32,450 shares of common stock in three transactions on September 28 and 29, 2026. He sold 9,020 shares at $10.4973 per share on September 28 as a sell-to-cover for taxes associated with RSU vesting. He also sold 8,000 shares on September 28 at a weighted-average price of $10.5622 and 15,430 shares on September 29 at a weighted-average price of $10.7487. The latter two sales were made under a Rule 10b5-1 trading plan adopted May 22, 2026.
Kura Oncology, Inc. Chief Scientific Officer Burrows Francis exercised 30,000 fully vested stock options on September 24, 2026, at an exercise price of $6.15 per share, acquiring 30,000 common shares. He sold 20,726 shares that day at a weighted average price of $10.8325 per share. The transaction was described as a cashless exercise and sale of a portion to cover estimated payroll tax liability; the sale trades ranged from $10.82 to $10.85. The option row reported 0 options following the transaction and an expiration date of January 22, 2027.
Kura Oncology, Inc. (KURA) reported that Chief Financial Officer Jennifer Fulk received a grant of stock options covering 450,000 shares of common stock on September 8, 2026. The options have an exercise price of $12.52 per share and expire on September 7, 2036, and no shares were bought or sold.
The grant was reported as made pursuant to a Rule 10b5-1 trading plan. According to the vesting terms, one-fourth of the options vest on the one-year anniversary of the vesting commencement date, with the remainder vesting in monthly installments thereafter.
Kura Oncology, Inc. (KURA) disclosed that President and CEO Troy Edward Wilson, through the One Fish Two Fish Revocable Trust, purchased 100,000 shares of common stock on 2026-08-24 at a weighted average price of $12.39 per share, from individual trades between $11.47 and $12.85. Following this purchase, that trust held 479,194 shares indirectly, in addition to 300,000 shares held indirectly by the Lorax Charitable Remainder Unitrust and 435,456 shares held directly.
Kura Oncology, Inc. (KURA) reported that Chief Commercial Officer Brian T. Powl sold 4,345 shares of common stock on August 21, 2026 at a weighted average price of $11.8903 per share. After this 10b5-1 plan trade, he held 169,269 shares of Kura Oncology common stock directly.
Kura Oncology, Inc. (KURA) reported that Chief Legal Officer Teresa Brophy Bair sold 31,487 shares of common stock on August 19, 2026 in an open-market transaction at a weighted average price of $12.63 per share, with trade prices ranging from $12.44 to $12.83. These shares had been acquired upon vesting of restricted stock units between January 26, 2024 and January 26, 2026. After this sale, she directly holds 195,444 shares of Kura Oncology common stock. The sale was effected under a Rule 10b5-1 trading plan adopted on May 20, 2026.
Kura Oncology, Inc. director and President and CEO Troy Edward Wilson reported a purchase of 100,000 shares of Common Stock on 2026-08-17 at a weighted average price of $11.12 per share, executed in multiple trades between $10.87 and $11.31. The purchased shares are held indirectly by One Fish Two Fish Revocable Trust, bringing that trust’s reported holdings to 379,194 shares following the transaction. Additional reported positions include 300,000 shares held indirectly by Lorax Charitable Remainder Unitrust and 435,456 shares held directly by the reporting person.
Kura Oncology, Inc. Chief Medical Officer Mollie Leoni sold 84,929 shares of common stock in an open-market transaction on June 18, 2026 at a weighted average price of $9.8233 per share. The trades were executed in multiple lots at prices ranging from $9.56 to $9.98.
The shares sold had been acquired upon vesting of restricted stock units and performance restricted stock units between January 26, 2022 and January 26, 2026. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, 2026. Following this transaction, Leoni directly holds 182,345 Kura Oncology shares.
Kura Oncology, Inc. director Diane L. Parks received an option grant for 35,000 shares of common stock. The option has an exercise price of $8.77 per share and expires on June 3, 2036. According to the grant terms, it vests in full on the one-year anniversary of the grant date.
Kura Oncology director Michael Vasconcelles received a new stock option grant covering 35,000 shares of common stock. The option has an exercise price of $8.77 per share and was granted at no upfront cost. It vests in full on the one-year anniversary of the grant date and expires on June 3, 2036. Following this award, Vasconcelles holds options for 35,000 shares directly, reflecting a compensation-related grant rather than an open-market trade.
Kura Oncology, Inc. director Faheem Hasnain reported receiving an option grant to purchase 35,000 shares of common stock. The option has an exercise price of $8.77 per share and expires on June 3, 2036. Following this grant, Hasnain holds options for 35,000 shares. The award vests in full on the one-year anniversary of the grant date, making it a standard equity compensation grant rather than an open-market purchase.
Kura Oncology director Helen Louise Collins received a new stock option grant that increases her potential equity stake in the company. She was awarded options to purchase 35,000 shares of common stock at an exercise price of $8.77 per share. The options vest in full on the one-year anniversary of the grant date and expire on June 3, 2036. Following this grant, she holds options covering 35,000 shares directly.
Kura Oncology director Carol Schafer received a grant of stock options, acquiring options to purchase 35,000 shares of common stock at an exercise price of $8.77 per share. These options vest in full on the one-year anniversary of the grant date and expire on June 3, 2036. Following this compensation-related award, Schafer holds 35,000 options directly, with no indication of open-market buying or selling in this filing.
Kura Oncology reported that director Mary T. Szela received an option grant to purchase 35,000 shares of common stock. The option has an exercise price of $8.77 per share and expires on June 3, 2036. It vests in full on the one-year anniversary of the grant date, and following this award she holds 35,000 options directly.
Kura Oncology director Thomas Malley received a stock option grant covering 35,000 shares of common stock. The option has an exercise price of $8.77 per share and was reported as a grant or award, not an open-market purchase or sale.
The option vests in full on the one-year anniversary of the grant date and expires on June 3, 2036 if not exercised. Following this award, Malley’s reported derivative holdings in this option total 35,000 underlying shares, reflecting a compensation-related equity incentive rather than a discretionary trade.
Kura Oncology, Inc. Chief Commercial Officer Brian T. Powl sold 10,000 shares of common stock in an open-market transaction at $11.00 per share. After the sale, he held 173,614 shares directly. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025.
Kura Oncology, Inc. Chief Commercial Officer Brian T. Powl reported an open-market sale of 339 shares of common stock at $9.21 per share. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan. Following this sale, he directly holds 183,614 shares of Kura Oncology common stock.
Kura Oncology, Inc. Chief Operating Officer Kathleen Ford reported an open-market sale of 2,257 shares of common stock on May 19, 2026 at a weighted average price of $9.0752 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2025.
According to the filing, the 2,257 shares sold match 2,257 shares acquired on May 17, 2026 through the company’s Employee Stock Purchase Plan. After this transaction, Ford directly holds 153,560 shares of Kura Oncology common stock.
Kura Oncology, Inc. Chief Legal Officer Teresa Brophy Bair sold 2,256 shares of common stock in an open-market transaction at a weighted average price of $9.3795 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025.
According to the filing, the 2,256 shares sold had been acquired on May 17, 2026 through the company’s Employee Stock Purchase Plan. Following this transaction, Bair directly holds 226,931 shares of Kura Oncology common stock.
Kura Oncology, Inc. President and CEO Troy Edward Wilson exercised stock options to acquire 6,103 shares of common stock at $6.15 per share on March 23, 2026. These options were fully vested and, after the exercise, that option grant was fully used.
Following the transaction, he directly holds 435,456 shares of Kura Oncology common stock. The filing also shows indirect holdings of 279,194 shares held by One Fish Two Fish Revocable Trust and 300,000 shares held by Lorax Charitable Remainder Unitrust, reflecting additional ownership through related entities.
Kura Oncology director Thomas Malley exercised stock options to acquire 10,000 shares of common stock at $3.12 per share. The options were fully vested, and this exercise used his remaining options from that grant, leaving no options from it outstanding. After the transaction, he directly holds 10,000 common shares and indirectly holds 139,557 common shares through Mossrock Capital, LLC, where he serves as President with sole voting and investment power over those shares.
Kura Oncology’s Chief Commercial Officer Brian T. Powl reported routine share sales related to tax withholding on vested restricted stock units. On January 27, 2026, he sold 4,842 and 1,572 shares of common stock at prices of $8.4606 and $8.4607 per share, respectively, as sell-to-cover transactions for RSUs granted on January 2, 2025 and January 2, 2024. Following these sales, he directly owned 183,275 shares of Kura Oncology common stock.
Kura Oncology, Inc. Chief Operating Officer Kathleen Ford reported a small stock sale related to tax withholding. On 01/27/2026, she sold 1,813 shares of common stock at $8.4607 per share in a transaction coded “S.”
The filing explains this was a sell-to-cover for taxes tied to the vesting of a restricted stock unit granted on 01/26/2022. After this transaction, Ford beneficially owned 153,560 shares of Kura Oncology common stock in direct form.
Kura Oncology Chief Medical Officer Mollie Leoni reported routine share sales tied to tax withholding on restricted stock units (RSUs). On January 27, 2026, she sold a total of 8,180 shares of Kura Oncology common stock at $8.4607 per share in four transactions classified as "sell-to-cover" for RSU vesting taxes.
After these sales, Leoni directly beneficially owned 267,274 shares of Kura Oncology common stock, indicating she retains a substantial equity position while satisfying tax obligations from prior RSU awards.
Kura Oncology, Inc. senior vice president of finance and accounting Thomas James Doyle reported several small sales of common stock on January 27, 2026, each at $8.4607 per share. The transactions were sell-to-cover trades for taxes tied to vesting restricted stock units granted between 2022 and 2025.
After these sales, Doyle beneficially owns 145,167 Kura Oncology common shares directly and an additional 500 shares indirectly through his spouse’s 401(k) account, indicating he retains a substantial equity stake in the company following the tax-related transactions.
Kura Oncology, Inc. Chief Scientific Officer Francis Burrows reported a small sale of company stock in connection with tax withholding. On January 27, 2026, he sold 1,311 shares of common stock at $8.4607 per share in a sell-to-cover transaction for taxes tied to the vesting of a restricted stock unit granted on January 26, 2022.
After this transaction, Burrows beneficially owns 32,424 shares of Kura Oncology common stock, held directly.
Kura Oncology Chief Legal Officer Teresa Bair reported routine tax-related stock sales. On 01/27/2026, she sold 4,096, 2,335 and 4,777 shares of Kura Oncology common stock in three separate transactions, each at $8.4607 per share.
All three transactions were disclosed as sell-to-cover trades for taxes due on vesting restricted stock units granted on 02/16/23, 01/02/24 and 01/02/25. Following the last transaction, she directly beneficially owned 226,931 Kura Oncology shares.
Kura Oncology, Inc. Chief Medical Officer Mollie Leoni reported new equity awards. On 01/02/2026 she received 50,000 shares of common stock in the form of restricted stock units at a stated price of $0, increasing her directly held common stock to 275,454 shares. The RSUs vest in four equal annual installments on 1/26/2027, 1/26/2028, 1/26/2029 and 1/26/2030, tying the award to multi‑year service.
She was also granted an option to purchase 100,000 shares of common stock at an exercise price of $10.335. This stock option vests in 48 equal monthly installments starting on the grant date and is exercisable until 01/01/2036, providing long-term, performance-linked compensation.
Kura Oncology, Inc. reported an equity award to a senior executive. Chief Scientific Officer Francis Burrows received an option to purchase 185,000 shares of Kura Oncology common stock on January 2, 2026 at an exercise price of $10.335 per share. The option was granted as a new award and is held directly.
The option vests in 48 equal monthly installments starting on the grant date, spreading vesting over four years. It is exercisable until January 1, 2036, and covers 185,000 underlying shares of common stock. Following this grant, Burrows beneficially owns 185,000 derivative securities in the form of this stock option.
Kura Oncology, Inc. (KURA) reported insider equity activity by its Chief Legal Officer on a Form 4. On 11/13/2025, 48,900 shares of common stock were acquired at a price of $0, reflecting vesting tied to performance-based restricted stock units (PSUs). On 11/14/2025, 8,804 shares were sold at $11.1769 in a sell-to-cover transaction for taxes related to this vesting. These PSUs were granted on May 31, 2023 and vest based on specified development milestones and continued service. Following the reported transactions, the officer beneficially owned 188,139 shares of Kura Oncology common stock directly.
Kura Oncology, Inc. (KURA) President and CEO Troy E. Wilson reported the vesting of 182,500 shares of common stock on 11/13/2025. These shares relate to performance-based restricted stock units (PSUs) originally granted on May 31, 2023, which vest upon achievement of specified development milestones and the one-year anniversary of each milestone, subject to continued service. The filing states that the performance criteria for one development milestone were met on November 13, 2025, triggering vesting of one-sixth of the underlying shares at a price of $0 per share. Following this transaction, Wilson beneficially owns 429,353 shares directly, 279,194 shares indirectly through the One Fish Two Fish Revocable Trust, and 300,000 shares indirectly through the Lorax Charitable Remainder Unitrust.
Kura Oncology, Inc. reported an insider equity transaction by its Chief Medical Officer, Mollie Leoni. On 11/13/2025 she acquired 82,500 shares of common stock at a reported price of $0 following the vesting of performance-based restricted stock units tied to a development milestone. On 11/14/2025 she sold 15,485 shares of common stock at $11.1769 per share in a sell-to-cover transaction for taxes related to that vesting. After these transactions, she directly beneficially owned 225,454 shares of Kura Oncology common stock.
Kura Oncology, Inc. (KURA) senior vice president of finance and accounting Thomas Doyle reported equity transactions in a Form 4. On 11/13/2025, he acquired 24,967 shares of common stock at $0, raising his direct holdings to 134,796 shares. On 11/14/2025, he sold 4,539 shares of common stock at $11.1769 per share, leaving 130,257 shares held directly. The sale was described as a sell-to-cover for taxes tied to the vesting of performance-based restricted stock units granted on May 31, 2023, after a specified development milestone was met on November 13, 2025. He also holds 500 shares indirectly through his spouse's 401(k).
Kura Oncology, Inc. (KURA) reported an insider equity transaction by its Chief Operating Officer. On 11/13/2025, the officer acquired 48,900 shares of common stock at $0, reflecting the vesting of performance-based restricted stock units after a development milestone was achieved. On 11/14/2025, 6,902 shares were sold at $11.1769 in a sell-to-cover transaction for taxes tied to this vesting. Following these transactions, the officer directly beneficially owned 105,373 shares of Kura Oncology common stock.